-
JBCRG-03
Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer
- Status
-
Study Closed
- Objectives
-
To evaluate the effect and safety of Docetaxel followed by FEC as primary systemic chmeotehrapy
- Subjects
-
- Endpoints
-
Primary endpoint: Pathological responce, safety ,Secondary endpoints: Clinical response, Breast conserving rate, Overall survival, Disease free survival
- Trial Period
-
Jul 2005 - Dec 2009 (Registration: 1 year, Follow-up study: 3 years)
- Lead Principal Investigator
-
Hiroji Iwata (Department of Breast Oncology, Aichi Cancer Center Hospital)
- Target Sample Size
-
130
- Regimen
-
Doc75 q3wx4->FEC100q3W×4
- Source of Funding
-
ACRO: Advanced Clinical Research Organization
- Conference Presentation
-
Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial
- Articles and Publications
-
Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer
- UMIN-ID
-
C000000291
- jRCT
-
- Memo
-
- COI Disclosure
-
